Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A OTT

Showing results (621-630 of 667) with videos related to

Pageof 67
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2016
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid TumorsAung Naing, Kyriakos P Papadopoulos, Karen A Autio, et al.
NPJ Genomic Medicine|April 10, 2026
Clinical validation of a high-performance somatic exome sequencing assay: from target-enrichment strategy to variant callingJunko Tsuji, Micah Rickles-Young, Justin Abreu, et al.
The Oncologist|May 30, 2013
Ipilimumab for patients with advanced mucosal melanomaMichael A Postow, Jason J Luke, Mark J Bluth, et al.
Nature|March 19, 2026
Thymic health and immunotherapy outcomes in patients with cancerSimon Bernatz, Vasco Prudente, Suraj Pai, et al.
The Lancet. Oncology|September 14, 2016
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trialF Stephen Hodi, Jason Chesney, Anna C Pavlick, et al.
JAMA Oncology|December 4, 2015
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune DisordersDouglas B Johnson, Ryan J Sullivan, Patrick A Ott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2018
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028Patrick A Ott, Yung-Jue Bang, Sarina A Piha-Paul, et al.
Science (New York, N.Y.)|October 13, 2018
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapyRazvan Cristescu, Robin Mogg, Mark Ayers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2020
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I TrialJason J Luke, Benjamin E Onderdonk, Sandeep R Bhave, et al.
The Lancet. Oncology|June 9, 2016
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trialScott J Antonia, José A López-Martin, Johanna Bendell, et al.
Pageof 67

Showing results (621-630 of 667) with videos related to

Sort By:
Pageof 67
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2016
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid TumorsAung Naing, Kyriakos P Papadopoulos, Karen A Autio, et al.
NPJ Genomic Medicine|April 10, 2026
Clinical validation of a high-performance somatic exome sequencing assay: from target-enrichment strategy to variant callingJunko Tsuji, Micah Rickles-Young, Justin Abreu, et al.
The Oncologist|May 30, 2013
Ipilimumab for patients with advanced mucosal melanomaMichael A Postow, Jason J Luke, Mark J Bluth, et al.
Nature|March 19, 2026
Thymic health and immunotherapy outcomes in patients with cancerSimon Bernatz, Vasco Prudente, Suraj Pai, et al.
The Lancet. Oncology|September 14, 2016
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trialF Stephen Hodi, Jason Chesney, Anna C Pavlick, et al.
JAMA Oncology|December 4, 2015
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune DisordersDouglas B Johnson, Ryan J Sullivan, Patrick A Ott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2018
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028Patrick A Ott, Yung-Jue Bang, Sarina A Piha-Paul, et al.
Science (New York, N.Y.)|October 13, 2018
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapyRazvan Cristescu, Robin Mogg, Mark Ayers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2020
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I TrialJason J Luke, Benjamin E Onderdonk, Sandeep R Bhave, et al.
The Lancet. Oncology|June 9, 2016
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trialScott J Antonia, José A López-Martin, Johanna Bendell, et al.
Pageof 67